TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dyspnea Self-Management: Internet or Face-to-Face
Brief Summary: Chronic obstructive pulmonary disease, including emphysema and chronic bronchitis, is the fourth most common cause of death and the second leading cause of disability in the United States. COPD is estimated to be responsible for more than 13.4 million physician visits and 13% of hospitalizations nationally. These hospitalizations are usually caused by acute exacerbations characterized by an increase in symptoms including dyspnea or shortness of breath (SOB), cough, wheezing, and sputum production. The significant disability for people with COPD is primarily due to the symptom of dyspnea (shortness of breath) that affects an individual's quality of life more than does the physiological impairment. Despite optimal medical and pharmacological therapy, most people with COPD continue to suffer from chronic and progressive dyspnea and other symptoms of cough and fatigue.

We have previously shown that an individualized face-to-face dyspnea self-management program was effective in improving dyspnea with activities of daily living (ADL), physical functioning, and self-efficacy for managing dyspnea. Using an experimental longitudinal design, the i-DSMP will be compared to the Face-to-Face Dyspnea Self-Management Program (f-DSMP) and to an Attention Control (AC) intervention


Options:
A: Arm Label: 1: i-DSMP; Type: EXPERIMENTAL; Interventions: Behavioral: Internet DSMP | Arm Label: 2: f-DSMP; Type: EXPERIMENTAL; Interventions: Behavioral: Face-to-Face Dyspnea Self-management | Arm Label: 3: AC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: Internet DSMP; Assigned to Arm(s): 1: i-DSMP | Intervention Type: BEHAVIORAL; Name: Face-to-Face Dyspnea Self-management; Assigned to Arm(s): 2: f-DSMP | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): 3: AC
B: Arm Label: COPD Web; Type: EXPERIMENTAL; Interventions: Behavioral: COPD Web | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: COPD Web; Assigned to Arm(s): COPD Web
C: Arm Label: Psychoeducative intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducative intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducative intervention; Assigned to Arm(s): Psychoeducative intervention
D: Arm Label: Disease management program; Type: EXPERIMENTAL; Interventions: Other: Disease Management | Arm Label: Usual site management; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual site management | Intervention Type: OTHER; Name: Disease Management; Assigned to Arm(s): Disease management program | Intervention Type: OTHER; Name: Usual site management; Assigned to Arm(s): Usual site management

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dyspnea Self-Management: Internet or Face-to-Face
Brief Summary: Chronic obstructive pulmonary disease, including emphysema and chronic bronchitis, is the fourth most common cause of death and the second leading cause of disability in the United States. COPD is estimated to be responsible for more than 13.4 million physician visits and 13% of hospitalizations nationally. These hospitalizations are usually caused by acute exacerbations characterized by an increase in symptoms including dyspnea or shortness of breath (SOB), cough, wheezing, and sputum production. The significant disability for people with COPD is primarily due to the symptom of dyspnea (shortness of breath) that affects an individual's quality of life more than does the physiological impairment. Despite optimal medical and pharmacological therapy, most people with COPD continue to suffer from chronic and progressive dyspnea and other symptoms of cough and fatigue.

We have previously shown that an individualized face-to-face dyspnea self-management program was effective in improving dyspnea with activities of daily living (ADL), physical functioning, and self-efficacy for managing dyspnea. Using an experimental longitudinal design, the i-DSMP will be compared to the Face-to-Face Dyspnea Self-Management Program (f-DSMP) and to an Attention Control (AC) intervention


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Tele rehab | Intervention Type: BEHAVIORAL; Name: Tele rehab; Assigned to Arm(s): Intervention group
B: Arm Label: Hospital-based; Type: EXPERIMENTAL; Interventions: Behavioral: Pulmonary rehabilitation (teaching and exercise) | Arm Label: Home-Based; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Pulmonary rehabilitation (teaching and exercise) | Intervention Type: BEHAVIORAL; Name: Pulmonary rehabilitation (teaching and exercise); Assigned to Arm(s): Home-Based, Hospital-based
C: Arm Label: 1: i-DSMP; Type: EXPERIMENTAL; Interventions: Behavioral: Internet DSMP | Arm Label: 2: f-DSMP; Type: EXPERIMENTAL; Interventions: Behavioral: Face-to-Face Dyspnea Self-management | Arm Label: 3: AC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: Internet DSMP; Assigned to Arm(s): 1: i-DSMP | Intervention Type: BEHAVIORAL; Name: Face-to-Face Dyspnea Self-management; Assigned to Arm(s): 2: f-DSMP | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): 3: AC
D: Arm Label: Telerehabilitation; Type: EXPERIMENTAL; Interventions: Other: telerehabilitation | Arm Label: Standard chronic care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: telerehabilitation; Assigned to Arm(s): Telerehabilitation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dyspnea Self-Management: Internet or Face-to-Face
Brief Summary: Chronic obstructive pulmonary disease, including emphysema and chronic bronchitis, is the fourth most common cause of death and the second leading cause of disability in the United States. COPD is estimated to be responsible for more than 13.4 million physician visits and 13% of hospitalizations nationally. These hospitalizations are usually caused by acute exacerbations characterized by an increase in symptoms including dyspnea or shortness of breath (SOB), cough, wheezing, and sputum production. The significant disability for people with COPD is primarily due to the symptom of dyspnea (shortness of breath) that affects an individual's quality of life more than does the physiological impairment. Despite optimal medical and pharmacological therapy, most people with COPD continue to suffer from chronic and progressive dyspnea and other symptoms of cough and fatigue.

We have previously shown that an individualized face-to-face dyspnea self-management program was effective in improving dyspnea with activities of daily living (ADL), physical functioning, and self-efficacy for managing dyspnea. Using an experimental longitudinal design, the i-DSMP will be compared to the Face-to-Face Dyspnea Self-Management Program (f-DSMP) and to an Attention Control (AC) intervention


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Device: half-yearly monitoring routine | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: half-yearly monitoring routine; Assigned to Arm(s): A
B: Arm Label: Group 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Behavioral: COPD Self-management Education | Intervention Type: BEHAVIORAL; Name: COPD Self-management Education; Assigned to Arm(s): Group 2
C: Arm Label: 1: i-DSMP; Type: EXPERIMENTAL; Interventions: Behavioral: Internet DSMP | Arm Label: 2: f-DSMP; Type: EXPERIMENTAL; Interventions: Behavioral: Face-to-Face Dyspnea Self-management | Arm Label: 3: AC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: Internet DSMP; Assigned to Arm(s): 1: i-DSMP | Intervention Type: BEHAVIORAL; Name: Face-to-Face Dyspnea Self-management; Assigned to Arm(s): 2: f-DSMP | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): 3: AC
D: Arm Label: Tool + Self-management Support Program; Type: EXPERIMENTAL; Interventions: Device: Tool, Behavioral: Self-management Support Program | Arm Label: Self- management Support Program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management Support Program | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Tool; Assigned to Arm(s): Tool + Self-management Support Program | Intervention Type: BEHAVIORAL; Name: Self-management Support Program; Assigned to Arm(s): Self- management Support Program, Tool + Self-management Support Program

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dyspnea Self-Management: Internet or Face-to-Face
Brief Summary: Chronic obstructive pulmonary disease, including emphysema and chronic bronchitis, is the fourth most common cause of death and the second leading cause of disability in the United States. COPD is estimated to be responsible for more than 13.4 million physician visits and 13% of hospitalizations nationally. These hospitalizations are usually caused by acute exacerbations characterized by an increase in symptoms including dyspnea or shortness of breath (SOB), cough, wheezing, and sputum production. The significant disability for people with COPD is primarily due to the symptom of dyspnea (shortness of breath) that affects an individual's quality of life more than does the physiological impairment. Despite optimal medical and pharmacological therapy, most people with COPD continue to suffer from chronic and progressive dyspnea and other symptoms of cough and fatigue.

We have previously shown that an individualized face-to-face dyspnea self-management program was effective in improving dyspnea with activities of daily living (ADL), physical functioning, and self-efficacy for managing dyspnea. Using an experimental longitudinal design, the i-DSMP will be compared to the Face-to-Face Dyspnea Self-Management Program (f-DSMP) and to an Attention Control (AC) intervention


Options:
A: Arm Label: 1: i-DSMP; Type: EXPERIMENTAL; Interventions: Behavioral: Internet DSMP | Arm Label: 2: f-DSMP; Type: EXPERIMENTAL; Interventions: Behavioral: Face-to-Face Dyspnea Self-management | Arm Label: 3: AC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: Internet DSMP; Assigned to Arm(s): 1: i-DSMP | Intervention Type: BEHAVIORAL; Name: Face-to-Face Dyspnea Self-management; Assigned to Arm(s): 2: f-DSMP | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): 3: AC
B: Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Internet-mediated Walking Program; Type: OTHER; Interventions: Behavioral: automated internet-mediated walking program | Intervention Type: BEHAVIORAL; Name: automated internet-mediated walking program; Assigned to Arm(s): Internet-mediated Walking Program | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Intervention Type: BEHAVIORAL; Name: Internet-based Dyspnea Self-Management Program; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Face-to-face Dyspnea Self-Management Program; Assigned to Arm(s): N/A
D: Arm Label: MOBILE-A; Type: EXPERIMENTAL; Interventions: Behavioral: Coached exercise persistence intervention | Arm Label: MOBILE-B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Monitored exercise persistence intervention | Intervention Type: BEHAVIORAL; Name: Coached exercise persistence intervention; Assigned to Arm(s): MOBILE-A | Intervention Type: BEHAVIORAL; Name: Self-Monitored exercise persistence intervention; Assigned to Arm(s): MOBILE-B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing the Quality of Life and Independence of Persons Disabled by Severe Mental Illness Through Supported Employment
Brief Summary: The primary aim of the study was to determine the effectiveness of a form of supported employment, Individual Placement and Support (IPS) compared to existing good quality rehabilitation and vocational services for people with psychotic illnesses in terms of 'open' employment outcomes (in the competitive labour market), and to examine its relative effectiveness in the context of different European welfare systems and labour markets. The primary hypothesis was that IPS patients would be more likely to obtain open employment than control service patients. Secondary hypotheses were that they would be in open employment for longer than the control patients, and that they would not spend more time in hospital.


Options:
A: Arm Label: Integrated Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Treatment | Arm Label: Community Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Community Care | Intervention Type: BEHAVIORAL; Name: Integrated Treatment; Assigned to Arm(s): Integrated Treatment | Intervention Type: BEHAVIORAL; Name: Community Care; Assigned to Arm(s): Community Care
B: Arm Label: Individual Placement and Support (IPS); Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and support (IPS) | Arm Label: IPS plus; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and support (IPS), Behavioral: IPS plus | Arm Label: Standard intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Individual Placement and support (IPS); Assigned to Arm(s): IPS plus, Individual Placement and Support (IPS) | Intervention Type: BEHAVIORAL; Name: IPS plus; Assigned to Arm(s): IPS plus
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Family-aided Assertive Community Treatment; Type: EXPERIMENTAL; Interventions: Drug: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Behavioral: Psychoeducational multifamily group treatment, Behavioral: Supported employment and education | Intervention Type: DRUG; Name: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine; Assigned to Arm(s): Family-aided Assertive Community Treatment | Intervention Type: BEHAVIORAL; Name: Psychoeducational multifamily group treatment; Assigned to Arm(s): Family-aided Assertive Community Treatment | Intervention Type: BEHAVIORAL; Name: Supported employment and education; Assigned to Arm(s): Family-aided Assertive Community Treatment
D: Intervention Type: PROCEDURE; Name: Individual placement and support (vocational rehabilitation); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Teen Sexual Behavior: A Clinic-Based Approach
Brief Summary: This study will evaluate the effectiveness of a parent-based intervention in reducing sexual risk behavior in high-risk Latino and African-American adolescents.


Options:
A: Intervention Type: DEVICE; Name: Ortho All-Flex diaphragm and Replens lubricant gel; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Increased access to emergency contraceptive pills; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Health Improvement Project for Teens on HIV Prevention | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Health Improvement Project for Teens on HIV Prevention | Intervention Type: BEHAVIORAL; Name: Health Improvement Project for Teens on HIV Prevention; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Families Talking Together | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active control on hygiene and nutrition | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Active control on hygiene and nutrition; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Families Talking Together; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient-Centered Disease Management for Heart Failure Trial
Brief Summary: The purpose of this study is to evaluate a patient-centered disease management intervention for VA patients with heart failure.


Options:
A: Arm Label: AB sequence; Type: EXPERIMENTAL; Interventions: Other: Usual care followed by the use of HeartHab application | Arm Label: BA sequence; Type: EXPERIMENTAL; Interventions: Other: Use of HeartHab application followed by usual care | Intervention Type: OTHER; Name: Use of HeartHab application followed by usual care; Assigned to Arm(s): BA sequence | Intervention Type: OTHER; Name: Usual care followed by the use of HeartHab application; Assigned to Arm(s): AB sequence
B: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group I; Type: EXPERIMENTAL; Interventions: Behavioral: self-regulation | Intervention Type: BEHAVIORAL; Name: self-regulation; Assigned to Arm(s): Intervention Group I
C: Arm Label: Intervention; Type: N/A; Interventions: Behavioral: Intervention | Arm Label: Usual Care; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention
D: Arm Label: A; Type: OTHER; Interventions: Other: A: Home-Based exercise after Cardiac Rehabilitation | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: A: Home-Based exercise after Cardiac Rehabilitation; Assigned to Arm(s): A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient-Centered Disease Management for Heart Failure Trial
Brief Summary: The purpose of this study is to evaluate a patient-centered disease management intervention for VA patients with heart failure.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: Behavioral: Health coaching | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): Usual Care
B: Arm Label: Talking Rx; Type: EXPERIMENTAL; Interventions: Behavioral: Talking Rx | Arm Label: Usual Care, Prescriptions and Counselling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Talking Rx; Assigned to Arm(s): Talking Rx
C: Arm Label: Intervention; Type: N/A; Interventions: Behavioral: Intervention | Arm Label: Usual Care; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention
D: Arm Label: remote monitoring; Type: EXPERIMENTAL; Interventions: Device: heart failure remote patient monitoring system | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: heart failure remote patient monitoring system; Assigned to Arm(s): remote monitoring

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient-Centered Disease Management for Heart Failure Trial
Brief Summary: The purpose of this study is to evaluate a patient-centered disease management intervention for VA patients with heart failure.


Options:
A: Arm Label: Expert instructor debriefing; Type: ACTIVE_COMPARATOR; Interventions: Other: Expert instructor debriefing | Arm Label: Peer-led debriefing; Type: EXPERIMENTAL; Interventions: Other: Peer-led debriefing | Intervention Type: OTHER; Name: Peer-led debriefing; Assigned to Arm(s): Peer-led debriefing | Intervention Type: OTHER; Name: Expert instructor debriefing; Assigned to Arm(s): Expert instructor debriefing
B: Arm Label: Intervention; Type: N/A; Interventions: Behavioral: Intervention | Arm Label: Usual Care; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Information feedback | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information feedback | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 2
D: Arm Label: 3-day post-graduate course; Type: ACTIVE_COMPARATOR; Interventions: Other: 3-day post-graduate course | Arm Label: Combined implementation strategy; Type: EXPERIMENTAL; Interventions: Other: Combined implementation strategy | Intervention Type: OTHER; Name: 3-day post-graduate course; Assigned to Arm(s): 3-day post-graduate course | Intervention Type: OTHER; Name: Combined implementation strategy; Assigned to Arm(s): Combined implementation strategy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autologous Hemopoietic Stem Cell Support and Maintenance Treatment With Interferon-a Versus Thalidomide Versus Thalidomide / Velcade in Untreated Patients With Multiple Myeloma Less Than 65 Yrs Old
Brief Summary: The primary objective is to compare safety and efficacy of three induction treatments: VBMCP-VBAD / Velcade versus Thalidomide / Dexamethasone versus Velcade / Thalidomide / Dexamethasone. The second one is to evaluate the ability of stem cell mobilization after the treatments in order to do an autologous transplant. Otherwise this study wants to compare the safety and efficacy of the maintenance treatments: Interferón a-2b versus Thalidomide versus Thalidomide/Velcade.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: VELCADE Administered by subcutaneous injection | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: VELCADE Administered by intravenous infusion | Intervention Type: DRUG; Name: VELCADE Administered by subcutaneous injection; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: VELCADE Administered by intravenous infusion; Assigned to Arm(s): 2
B: Arm Label: VDR; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: Revlimid (lenalidomide) | Arm Label: VDCR; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide, Drug: Revlimid (lenalidomide) | Arm Label: VDC; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide | Arm Label: VDC-mod; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide | Intervention Type: DRUG; Name: VELCADE (bortezomib); Assigned to Arm(s): VDC, VDC-mod, VDCR, VDR | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): VDC, VDC-mod, VDCR, VDR | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): VDC, VDC-mod, VDCR | Intervention Type: DRUG; Name: Revlimid (lenalidomide); Assigned to Arm(s): VDCR, VDR
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: VBMCP/VBAD/Velcade | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide/Dexamethasone | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Velcade/Thalidomide/Dexamethasone | Intervention Type: DRUG; Name: VBMCP/VBAD/Velcade; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Thalidomide/Dexamethasone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Velcade/Thalidomide/Dexamethasone; Assigned to Arm(s): C
D: Intervention Type: DRUG; Name: Velcade; Assigned to Arm(s): N/A

Answer: C